Rocuronium

PRESENTATION:	Ampoules containing 100mg/10ml and 50mg/5ml.
INDICATION:	Second line treatment for muscle relaxation in ICU patients when atracurium supply not available or not suitable. Rocuronium is an intermediate non-depolarising neuromuscular blocking drug.
DOSE AND ADMINISTRATION:	ICU STANDARD INTRAVENOUS INFUSION IV bolus: 0.6 mg/kg. IV infusion: Administered undiluted e.g. 500mg in a 50ml syringe. Usual maintenance doses are between 0.3 - 0.6 mg/kg/hr. For a 70kg patient, this would equate to 2.1-4.2ml/h.
CONCENTRATION:	10mg/1ml.
MONITORING:	Monitoring of neuromuscular function using train-of-four peripheral nerve stimulation, is recommended during the use of rocuronium in order to individualise dosage requirements.
STABILITY:	Physically and chemically stable for 24 hours at room temperature.
OTHER INFORMATION:	Rocuronium has a low pH and may cause venous irritation and tissue damage in cases of extravasation. If a CVC is unavailable, administer via a large peripheral vein and monitor closely.

References

1. Rocuronium 10mg/ml injection, 2017. Hamlen. Summary of Product Characteristics. Available from: https://www.medicines.org.uk/emc/product/553/smpc (Revision of text 05/06/20)
2. United Kingdom Clinical Pharmacy Association, 2012. Minimum Infusion Volumes. Fourth Edition.
3. Rocuronium Bromide, Injectable Medicines Guide, Medusa. Accessed January 2022

Title: Rocuronium	
ID:	Authors: Mairi Cromarty
Category:	Document Version: 2.0
Status Draft/Final: Final	Review Date: March 2024
Authoriser: Lothian Critical Care QIT Editorial Group	Authorisation Date: March 2022
Date added to Intranet: March 2022	
Key Words **Comments**	